Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18862780 | 0.87 | VCAM1 (0.58) | VCAM1MAPTGAAALDH1A1LMNA | |
| SCHEMBL31450151 | 0.87 | VCAM1 (0.58) | VCAM1MAPTGAAALDH1A1LMNA | |
| SCHEMBL5734347 | 0.85 | VCAM1 (0.68) | VCAM1MAPTALDH1A1LMNAHPGD | |
| SCHEMBL30863327 | 0.83 | VCAM1 (0.66) | VCAM1MAPTALDH1A1LMNAHPGD | |
| SCHEMBL9118439 | 0.83 | KMT2A (0.64) | MAPTGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL531728 | 0.82 | VCAM1 (0.64) | VCAM1MAPTALDH1A1LMNAHPGD | |
| SCHEMBL193275 | 0.82 | TSHR (0.68) | VCAM1MAPTALDH1A1LMNAHPGD | |
| SCHEMBL13858799 | 0.82 | VCAM1 (0.64) | VCAM1MAPTALDH1A1LMNAHPGD | |
| SCHEMBL30443852 | 0.82 | TSHR (0.68) | VCAM1MAPTALDH1A1LMNAHPGD | |
| SCHEMBL30525281 | 0.82 | VCAM1 (0.64) | VCAM1MAPTGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567387-A | Method for preparing benzoxazine-4-ketone series compounds by using nitroaromatic hydrocarbon | 南京德川医药科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4648762-A2 | PPARG MODULATORS | University of Florida Research Foundation, Incorporated (US) | 2025-11-19 | — | — | EP | disclosed |
| US-RE50594-E1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-09-23 | — | — | US | disclosed |
| EP-4615581-A2 | FUSED MULTICYCLIC COMPOUNDS AND THEIR USE AS PARP1 INHIBITORS | Laekna Pharmaceutical Ningbo Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| CN-119899184-A | Beta-carboline compound, preparation method thereof and application thereof in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2025-04-29 | — | — | CN | disclosed |
| WO-2025054361-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-119569739-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119569740-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20080009510-A1 | Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-10 | — | — | US | disclosed |
| CN-101065357-A | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK & CO INC (US) | 2007-10-31 | — | — | CN | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1819674-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006132811-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006058064-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20050203078-A1 | Inhibitors of factor Xa or related serine proteases; thrombosis; benzamide derivatives with benzimidazole, indole or imidazo(1,2-a)pyridine rings; e.g. 4-(azepan-2-on-1-yl)-N-[(1R)-1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxy-ethyl]-3-methyl-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | VCAM1 2185/4885MAPT 3521/4885GAA 2555/4885 |
| US-20080009510-A1 | Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | VCAM1 2778/4885MAPT 3208/4885GAA 215/4885 |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | VCAM1 1228/4885MAPT 4827/4885GAA 3802/4885 |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | VCAM1 1503/4885MAPT 1347/4885GAA 504/4885 |
| US-20050203078-A1 | Inhibitors of factor Xa or related serine proteases; thrombosis; benzamide derivatives with benzimidazole, indole or imidazo(1,2-a)pyridine rings; e.g. 4-(azepan-2-on-1-yl)-N-[(1R)-1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxy-ethyl]-3-methyl-benzamide | F12, TFPI, F11 | VCAM1 517/4885MAPT 2366/4885GAA 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.